Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Discoidin domain receptor family member 1 (DDR1) is a unique receptor tyrosine kinase that is activated by various types of collagen rather than soluble growth factors (UniProt: Q08345). The extracellular domain (ECD) of DDR1 contains a discoidin homology motif that is essential for its interaction with collagen fibers in the extracellular matrix (ECM) (PMID: 28938308). Upon collagen binding to the ECD, DDR1 undergoes a slow and sustained autophosphorylation of its intracellular kinase domain, triggering signaling pathways such as MAPK/ERK and PI3K/Akt that regulate cell adhesion, migration, and survival (PMID: 30107159). DDR1 is predominantly expressed in epithelial cells and plays a vital role in tissue development and wound healing (NCBI Gene: 780). In disease states, DDR1 is often upregulated and contributes significantly to the progression of various cancers, including breast, lung, and pancreatic carcinomas, by promoting metastasis and chemoresistance (PMID: 28938308). It also plays a central role in the pathogenesis of fibrotic diseases, such as idiopathic pulmonary fibrosis and chronic kidney disease, by enhancing collagen production and inflammatory responses (PMID: 30107159). Therapeutic targeting of DDR1 involves small-molecule inhibitors that block its kinase activity or monoclonal antibodies that specifically target the extracellular domain to prevent collagen binding and receptor activation (PMID: 22532586).
Inhibition of collagen-induced receptor autophosphorylation and downstream signaling pathways (PMID: 30107159). Small-molecule inhibitors typically act as ATP-competitive inhibitors of the intracellular kinase domain, while monoclonal antibodies target the extracellular domain to sterically hinder collagen binding and prevent receptor dimerization and activation (PMID: 30107159, PMID: 22532586).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Discoidin domain receptor family member 1 (DDR1) (DDR1).